The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

The rising prevalence of overweight and obesity among adults in Malaysia is a growing concern, with statistics revealing that ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI launches shopping agent Operator; Etsy, eBay tick higher.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds ...

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity Allurion Technologies, Inc. (“Allurion” or the “Company ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent.

The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...